Liu Weihao, Li Xiaoli, Hang Bo, Wang Pu
Computer School, Hubei University of Arts and Science, Longzhong Road, Xiangyang, 441053, Hubei, China.
BMC Biol. 2025 May 15;23(1):136. doi: 10.1186/s12915-025-02238-3.
Identifying GPCR-compound interactions (GCI) plays a significant role in drug discovery and chemogenomics. Machine learning, particularly deep learning, has become increasingly influential in this domain. Large molecular models, due to their ability to capture detailed structural and functional information, have shown promise in enhancing the predictive accuracy of downstream tasks. Consequently, exploring the performance of these models in GCI prediction, as well as evaluating their effectiveness when integrated with other deep learning models, has emerged as a compelling research area. This paper aims to investigate these challenges.
This study introduces EnGCI, a novel model comprising two distinct modules. The MSBM integrates a graph isomorphism network (GIN) and a convolutional neural network (CNN) to extract features from GPCRs and compounds, respectively. These features are then processed by a Kolmogorov-Arnold network (KAN) for decision-making. The LMMBM utilizes two large-scale pre-trained models to extract features from compounds and GPCRs, and subsequently, KAN is again employed for decision-making. Each module leverages different sources of multimodal information, and their fusion enhances the overall accuracy of GPCR-compound interaction (GCI) prediction. Evaluating the EnGCI model on a rigorously curated GCI dataset, we achieved an AUC of approximately 0.89, significantly outperforming current state-of-the-art benchmark models.
The EnGCI model integrates two complementary modules: one that learns molecular features from scratch for the GPCR-compound interaction (GCI) prediction task, and another that extracts molecular features using pre-trained large molecular models. After further processing and integration, these multimodal information sources enable a more profound exploration and understanding of the complex interaction relationships between GPCRs and compounds. The EnGCI model offers a robust and efficient framework that enhances GCI predictive capabilities and has the potential to significantly contribute to GPCR drug discovery.
识别G蛋白偶联受体-化合物相互作用(GCI)在药物发现和化学基因组学中起着重要作用。机器学习,尤其是深度学习,在这一领域的影响力日益增强。大型分子模型由于能够捕捉详细的结构和功能信息,在提高下游任务的预测准确性方面显示出了前景。因此,探索这些模型在GCI预测中的性能,以及评估它们与其他深度学习模型集成时的有效性,已成为一个引人注目的研究领域。本文旨在研究这些挑战。
本研究介绍了EnGCI,这是一种由两个不同模块组成的新型模型。MSBM整合了图同构网络(GIN)和卷积神经网络(CNN),分别从G蛋白偶联受体和化合物中提取特征。然后,这些特征由柯尔莫哥洛夫-阿诺德网络(KAN)进行处理以进行决策。LMMBM利用两个大规模预训练模型从化合物和G蛋白偶联受体中提取特征,随后再次使用KAN进行决策。每个模块利用不同来源的多模态信息,它们的融合提高了G蛋白偶联受体-化合物相互作用(GCI)预测的整体准确性。在经过严格整理的GCI数据集上评估EnGCI模型,我们获得了约0.89的AUC,显著优于当前最先进的基准模型。
EnGCI模型整合了两个互补模块:一个是从零开始学习分子特征以进行G蛋白偶联受体-化合物相互作用(GCI)预测任务,另一个是使用预训练的大型分子模型提取分子特征。经过进一步处理和整合,这些多模态信息源能够更深入地探索和理解G蛋白偶联受体与化合物之间复杂的相互作用关系。EnGCI模型提供了一个强大而高效的框架,增强了GCI预测能力,并有潜力为G蛋白偶联受体药物发现做出重大贡献。